|
1
|
Liyanage PY, Hettiarachchi SD, Zhou Y,
Ouhtit A, Seven ES, Oztan CY, Celik E and Leblanc RM:
Nanoparticle-mediated targeted drug delivery for breast cancer
treatment. Biochim Biophys Acta Rev Cancer. 1871:419–433. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Al-Mulhim F, Alqosaib AI, Al-Muhnna A,
Fari K, Abdel-Ghany S, Rizk H, Prince AB, Isichei A and Sabit H:
CRISPR/Cas9-mediated activation of CDH1 suppresses metastasis of
breast cancer in rats. Electronic J Biotechnol. 53:54–60. 2021.
View Article : Google Scholar
|
|
3
|
Mao XD, Wei X, Xu T, Li TP and Liu KS:
Research progress in breast cancer stem cells: Characterization and
future perspectives. Am J Cancer Res. 12:3208–3222. 2022.PubMed/NCBI
|
|
4
|
Yousef AJA: Male breast cancer:
Epidemiology and risk factors. Semin Oncol. 44:267–272. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Momenimovahed Z and Salehiniya H:
Epidemiological characteristics of and risk factors for breast
cancer in the world. Breast Cancer (Dove Med Press). 11:151–164.
2019.PubMed/NCBI
|
|
6
|
Lei Y, Tang R, Xu J, Wang W, Zhang B, Liu
J, Yu X and Shi S: Applications of single-cell sequencing in cancer
research: Progress and perspectives. J Hematol Oncol. 14:912021.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wang K, Li L, Fu L, Yuan Y, Dai H, Zhu T,
Zhou Y and Yuan F: Integrated bioinformatics analysis the function
of RNA binding proteins (RBPs) and their prognostic value in breast
cancer. Front Pharmacol. 10:1402019. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Feng Y, Spezia M, Huang S, Yuan C, Zeng Z,
Zhang L, Ji X, Liu W, Huang B, Luo W, et al: Breast cancer
development and progression: Risk factors, cancer stem cells,
signaling pathways, genomics, and molecular pathogenesis. Genes
Dis. 5:77–106. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Marra A, Trapani D, Viale G, Criscitiello
C and Curigliano G: Practical classification of triple-negative
breast cancer: Intratumoral heterogeneity, mechanisms of drug
resistance, and novel therapies. NPJ Breast Cancer. 6:542020.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Sheikh A, Hussain SA, Ghori Q, Naeem N,
Fazil A, Giri S, Sathian B, Mainali P and Al Tamimi DM: The
spectrum of genetic mutations in breast cancer. Asian Pac J Cancer
Prev. 16:2177–2185. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Viedma-Rodríguez R, Baiza-Gutman L,
Salamanca-Gómez F, Diaz-Zaragoza M, Martínez-Hernández G,
Esparza-Garrido R, Velázquez-Flores MA and Arenas-Aranda D:
Mechanisms associated with resistance to tamoxifen in estrogen
receptor-positive breast cancer. Oncol Rep. 32:3–15. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Nagini S: Breast cancer: Current molecular
therapeutic targets and new players. Anticancer Agents Med Chem.
17:152–163. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kretschmer C, Sterner-Kock A, Siedentopf
F, Schoenegg W, Schlag PM and Kemmner W: Identification of early
molecular markers for breast cancer. Mol Cancer. 10:152011.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Thul PJ and Lindskog C: The human protein
atlas: A spatial map of the human proteome. Protein Sci.
27:233–244. 2018. View
Article : Google Scholar : PubMed/NCBI
|
|
15
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sutcliffe M, Radley G and Barton A:
Personalized medicine in rheumatic diseases: How close are we to
being able to use genetic biomarkers to predict response to TNF
inhibitors? Expert Rev Clin Immunol. 16:389–396. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ahmadzada T, Kao S, Reid G, Boyer M, Mahar
A and Cooper WA: An update on predictive biomarkers for treatment
selection in non-small cell lung cancer. J Clin Med. 7:1532018.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Pao W and Girard N: New driver mutations
in non-small-cell lung cancer. Lancet Oncol. 12:175–180. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Meng X, Huang Z, Teng F, Xing L and Yu J:
Predictive biomarkers in PD-1/PD-L1 checkpoint blockade
immunotherapy. Cancer Treat Rev. 41:868–876. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Sivapiragasam A, Kumar P, Sokol ES,
Albacker LA, Killian JK, Ramkissoon SH, Huang RSP, Severson EA,
Brown CA, Danziger N, et al: Predictive biomarkers for immune
checkpoint inhibitors in metastatic breast cancer. Cancer Med.
10:53–61. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Januškevičienė I and Petrikaitė V:
Heterogeneity of breast cancer: The importance of interaction
between different tumor cell populations. Life Sci. 239:1170092019.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ibragimova MK, Tsyganov MM and Litviakov
NV: Molecular-genetic portrait of breast cancer with triple
negative phenotype. Cancers (Basel). 13:53482021. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Melincovici CS, Boşca AB, Şuşman S,
Mărginean M and Mihu C, Istrate M, Moldovan IM, Roman AL and Mihu
C: Vascular endothelial growth factor (VEGF)-key factor in normal
and pathological angiogenesis. Rom J Morphol Embryol. 59:455–467.
2018.PubMed/NCBI
|
|
24
|
Kajdaniuk D, Marek B, Borgiel-Marek H and
Kos-Kudła B: Vascular endothelial growth factor (VEGF)-part 1: In
physiology and pathophysiology. Endokrynol Pol. 62:444–455.
2011.PubMed/NCBI
|
|
25
|
Yuan Z, Li Y, Zhang S, Wang X, Dou H, Yu
X, Zhang Z, Yang S and Xiao M: Extracellular matrix remodeling in
tumor progression and immune escape: from mechanisms to treatments.
Mol Cancer. 22:482023. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Insua-Rodríguez J and Oskarsson T: The
extracellular matrix in breast cancer. Adv Drug Deliv Rev.
97:41–55. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Park KC, Dharmasivam M and Richardson DR:
The role of extracellular proteases in tumor progression and the
development of innovative metal ion chelators that inhibit their
activity. Int J Mol Sci. 21:68052020. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Stelling MP, Motta JM, Mashid M, Johnson
WE, Pavão MS and Farrell NP: Metal ions and the extracellular
matrix in tumor migration. FEBS J. 286:2950–2964. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Tomita H, Tanaka K, Tanaka T and Hara A:
Aldehyde dehydrogenase 1A1 in stem cells and cancer. Oncotarget.
7:11018–11032. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Poturnajova M, Kozovska Z and Matuskova M:
Aldehyde dehydrogenase 1A1 and 1A3 isoforms-mechanism of activation
and regulation in cancer. Cell Signal. 87:1101202021. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Ciccone V, Morbidelli L, Ziche M and
Donnini S: How to conjugate the stemness marker ALDH1A1 with tumor
angiogenesis, progression, and drug resistance. Cancer Drug Resist.
3:26–27. 2020.PubMed/NCBI
|
|
32
|
Kong Y, Lyu N, Wu J, Tang H and Xie X,
Yang L, Li X, Wei W and Xie X: Breast cancer stem cell markers CD44
and ALDH1A1 in serum: Distribution and prognostic value in patients
with primary breast cancer. J Cancer. 9:3728–3735. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Li W, Ma H, Zhang J, Zhu L, Wang C and
Yang Y: Unraveling the roles of CD44/CD24 and ALDH1 as cancer stem
cell markers in tumorigenesis and metastasis. Sci Rep. 7:138562017.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Adorno-Cruz V and Liu H: Regulation and
functions of integrin α2 in cell adhesion and disease. Genes Dis.
6:16–24. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Gharibi A, La Kim S, Molnar J, Brambilla
D, Adamian Y, Hoover M, Hong J, Lin J, Wolfenden L and Kelber JA:
ITGA1 is a pre-malignant biomarker that promotes therapy resistance
and metastatic potential in pancreatic cancer. Sci Rep.
7:100602017. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Wei L, Yin F, Zhang W and Li L: ITGA1 and
cell adhesion-mediated drug resistance in ovarian cancer. Int J
Clin Exp Pathol. 10:5522–5529. 2017.
|
|
37
|
Han Y, Wang J and Xu B: Novel biomarkers
and prediction model for the pathological complete response to
neoadjuvant treatment of triple-negative breast cancer. J Cancer.
12:936–945. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Tong L, Wang S, Yang J, Zhang Q, Gu X, Mo
T, Luo Y, Zhang C, Zhang J and Liu Y: Combined ARHGEF6 and tumor
mutational burden may serve as a potential biomarker for
immunotherapy of lung adenocarcinoma. Heliyon. 9:e185012023.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Hemmesi K, Squadrito ML, Mestdagh P, Conti
V, Cominelli M, Piras IS, Sergi LS, Piccinin S, Maestro R, Poliani
PL, et al: miR-135a inhibits cancer stem cell-driven
medulloblastoma development by directly repressing Arhgef6
expression. Stem Cells. 33:1377–1389. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Guan X, Guan X, Dong C and Jiao Z: Rho
GTPases and related signaling complexes in cell migration and
invasion. Exp Cell Res. 388:1118242020. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Zhou W, Li X and Premont RT: Expanding
functions of GIT Arf GTPase-activating proteins, PIX Rho guanine
nucleotide exchange factors and GIT-PIX complexes. J Cell Sci.
129:1963–1974. 2016. View Article : Google Scholar : PubMed/NCBI
|
